Tag:
Mustek
Ghost Bites
Ghost Bites (AECI | Bidcorp | Blu Label | Fortress Real Estate | Hammerson | Motus | Mustek | Shaftesbury | Valterra Platinum)
A busy day of earnings news saw financials come in from AECI, Bidcorp, Blu Label, Hammerson, Motus, Mustek, Shaftesbury and Valterra Platinum. Fortress Real Estate gave shareholders a precise view of distributable income, with more details to follow.
Ghost Bites
Ghost Bites (Cell C | Ethos Capital | Mustek | KAP)
Cell C's maiden results as a listed company show us their growth engines, but also expense pressures. KAP is looking much better than before, and so is Mustek. Ethos Capital is repurchasing 41.5% of its shares in issue.
Ghost Bites
Ghost Bites (AfroCentric | Aspen | Novus – Mustek)
Aspen announced the disposal of Aspen APAC and the market loved it. AfroCentric is disposing of Activo and the market forgot to notice - for now, at least. And for Novus, a purchase of 3,000 shares has turned out to be very expensive in the Mustek deal.
Ghost Bites
Ghost Bites (Mr Price | NEPI Rockcastle)
Mr Price isn't backing off on the NKD deal, despite the absolute hatred for the transaction from the market. NEPI's pre-close update shows the importance of looking at per-share growth.
Ghost Bites
Ghost Bites (Curro | Hulamin | Labat Africa | Sanlam)
The Curro deal gets the green light. Sanlam is doing important deals in India across the various Shriram investments. Labat Africa's numbers look very interesting. Hulamin's full year numbers are likely to be awful.
Ghost Bites
Ghost Bites (Accelerate Property Fund | Deneb | eMedia | Frontier Transport | Growthpoint | HCI | KAL | Life Healthcare | Nampak |...
A huge day of news saw the HCI stable (including Deneb, eMedia, Frontier Transport and Tsogo Sun) release results. Growthpoint released a quarterly update. Nampak is a great turnaround story, while Accelerate Property Fund is also coming right. Numbers came in from KAL, Life Healthcare and Novus as well, while Sirius Real Estate announced another acquisition.
Ghost Bites
Ghost Bites (Aspen | ASP Isotopes | Boxer | Calgro M3 | Canal+ and MultiChoice)
Boxer's underlying story is good, but the IPO ruined profit growth. Canal+ will inward list on the JSE after the MultiChoice deal. Calgro M3's earnings fell this period based on infrastructure timing. ASP Isotopes locked in their biggest ever supply deal. Aspen is thrilled that Mounjaro can be prescribed for obesity in SA.
DealMakers
Who’s doing what this week in the South African M&A space?
Weekly summary of Merger & Acquisition activity by South African companies
